title: Surveillance for stage I testicular seminoma. Is it a good option?
abstract: Postorchidectomy treatment options in patients with stage I seminoma include surveillance (reserving treatment for patients who relapse), adjuvant radiation therapy (RT), and adjuvant chemotherapy. Adjuvant retroperitoneal RT remains the treatment of choice in most centers; however, the success of surveillance in stage I nonseminomatous germ cell testis tumors, the establishment of curative chemotherapy for advanced disease, and the improvements in CT have led to re-examination of the standard treatment approach. The available data from the surveillance and adjuvant RT series suggest that almost 100% of patients with stage I testicular seminoma are cured, whichever approach is chosen. This article presents an overview of the available information on all treatment options, the pros and cons of each approach, and indications for where surveillance fits into the armamentarium of clinicians dealing with this disease.
authors.affiliation: Department of Radiation Oncology, University of Toronto, Ontario, Canada.
authors.forename: P
authors.initials: P
authors.lastname: Warde
authors.forename: M A
authors.initials: MA
authors.lastname: Jewett
mesh_terms: D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D009367:Neoplasm Staging; D009919:Orchiectomy; D011159:Population Surveillance; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D012307:Risk Factors; D018239:Seminoma / Q000473:pathology / Q000517:prevention & control* / Q000532:radiotherapy / Q000601:surgery; D013736:Testicular Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000532:radiotherapy / Q000601:surgery; D016896:Treatment Outcome